Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Alliance Pharma to Acquire Drug Development Solutions Business of UK-Based LGC.

Document Cited in Related
Vincent

MANews-(C)2009-2022

US-based bioanalytical a contract research organisation (CRO) Alliance Pharma has agreed to acquire UK-based Drug Development Solutions (DDS), the bioanalytical business unit of life science tools company LGC, the company said.

Terms of the transaction were not disclosed.

US-based investment firm KKR will become an equal shareholder in the combined business alongside Ampersand Capital Partners.

Backed by Ampersand and KKR, Alliance and DDS plan to expand the company's geographic reach, broaden its laboratory capabilities and expand its service portfolio. The transaction is subject to regulatory approvals and expected to be completed in Q2 2022.

Alliance Pharma provides large and small molecule bioanalytical services, and a full suite of discovery Bioanalytical, DMPK, regulated bioanalysis, biomarker, LC-MS/MS, immunoassay, cell and gene therapy, and protein characterisation assays.

DDS is a European provider of Bioanalytical and Analytical and Materials Science Solutions to pharma, biopharma, consumer healthcare and consumer products clients.

Together, the combined entity will enable its clients...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT